Ocumetics Technology Corp. announced the successful completion of its latest animal studies. The lens design met and exceeded its expectations.

This is the first in a series of biocompatibility studies, the second of which is scheduled to commence in March 2023. The biocompatibility studies will take 3 months to complete, which means it should be able to begin first-in-human proof of concept studies in July or August of 2023.